Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $8,215,315.38 in Stock

Key Points

• CEO Sanj Patel sold 89,433 shares for about $8.2 million, reducing his direct ownership by 9.32% to 869,881 shares. The sale was made under a pre-arranged Rule 10b5-1 plan.
• Kiniksa shares rose 2.7% to $93.29. The company beat quarterly expectations, reporting EPS of $0.56 versus $0.37 expected and revenue of $285.97 million versus $260.66 million expected.
• Analyst sentiment is generally positive: seven analysts rate the stock Buy and two Hold, with a consensus price target of $100.57. Other company insiders also reported sizable sales, totaling about $25.4 million across several transactions, all under pre-arranged plans.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CEO Sanj Patel sold 89,433 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $91.86, for a total value of $8,215,315.38. Following the completion of the sale, the chief executive officer directly owned 869,881 shares in the company, valued at approximately $79,907,268.66. This represents a 9.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 2.7%

Shares of NASDAQ:KNSA traded up $2.49 on Tuesday, hitting $93.29. 1,021,631 shares of the company traded hands, compared to its average volume of 897,528. Kiniksa Pharmaceuticals International, plc has a 52 week low of $37.02 and a 52 week high of $98.48. The stock has a 50 day simple moving average of $79.67 and a 200-day simple moving average of $60.56. The company has a market cap of $7.28 billion, a PE ratio of 71.76 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to analysts' expectations of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. As a group, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c-)" rating in a research note on Wednesday, October 28th. Citigroup boosted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. The Goldman Sachs Group increased their target price on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a "buy" rating in a research note on Wednesday, October 28th. JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an "overweight" rating in a research note on Friday. Finally, Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, October 28th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $100.57.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ethic Inc. bought a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $726,000. Pictet Asset Management Holding SA raised its stake in Kiniksa Pharmaceuticals International by 41.3% during the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company's stock valued at $64,182,000 after buying an additional 251,578 shares during the last quarter. AlphaCentric Advisors LLC purchased a new stake in Kiniksa Pharmaceuticals International during the 3rd quarter valued at $596,000. Commonwealth Equity Services LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company's stock valued at $811,000 after buying an additional 237 shares during the period. Finally, Chicago Partners Investment Group LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at $226,000. Institutional investors own 53.95% of the company's stock.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.